ABSTRACT To investigate the role of the leader peptide in modulating secretion from living cells, we injected a synthetic peptide into Xenopus oocytes. The peptide consisted of the NH2-terminal leader sequence of mouse immunoglobulin light chain precursor. We found that the leader peptide has two different roles in regulating secretion from the oocytes. First, it competitively inhibits the synthesis of secretory and membrane proteins but not of cytoplasmic proteins. The inhibition occurs both with oocyte proteins and with proteins directed by coinjected myeloma mRNA. The inhibition reaches a maximum 2 hr after injection and decays within 3 hr. It appears to be mediated through the cell membrane, because "2I-labeled leader peptide segregates into the membrane fraction of microinjected oocytes simultaneously with the interference with methionine incorporation. A second role of the microinjected leader peptide is to induce a rapid acceleration in the rate of export of secretory proteins from the oocyte. The maximal enhancement effect is obtained upon injection of 50 ng of leader peptide per oocyte. It is not merely due to the small size, negative charge, or hydrophobicity of the peptide, because enhanced secretion does not occur when glucagon, poly-L-glutamic acid, or Triton X-100 is injected. Furthermore, immunoreaction of the peptide with specific antibodies prior to microinjection prevents the accelerated export. Our observations indicate that in Xenopwu oocytes, the leader peptide is involved in both translocation and later step(s) in the secretory pathway.
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Most secretory proteins are processed in the living cell from nascent polypeptide chains, extended at their NH2 terminus by the leader, or signal, peptide (1) (2) (3) . The leader peptide is involved in the vectorial translocation of nascent proteins across the membrane of the endoplasmic reticulum (1, (4) (5) (6) (7) (8) . The emergence of the leader peptide from the large ribosomal subunit is accompanied by a translation block, mediated by a cytoplasmic signal recognition protein, complex (9, 10) . This block is only released upon interaction of the complex with the "docking protein," a component of the endoplasmic reticulum membrane (10, 11) . Thus, the number of nascent chains for secretory proteins cannot exceed the number of available routes for translocation, and the leader peptide operates as a regulatory element at this step in the pathway for secretion.
After the release of the translation block, continued synthesis of secretory proteins resumes, coupled to translocation of the processed chains across the membrane (10). The leader peptide is then cleaved off the forming chains and is rapidly degraded (12) . The processed proteins are transferred into the cysterna of the rough endoplasmic reticulum and via small vesicles to the Golgi apparatus, to be packaged into secretory granules, which accumulate until secretion occurs (13) . One may postulate that additional regulatory mechanism(s) may also operate at these later steps in the secretory pathway. These would control the amount of sequestered proteins within the cell, so that it would not exceed the capacity of the cell to secrete proteins. One possibility for such regulation could be by acceleration of the rate of secretion of already processed and sequestered proteins. Therefore, we were interested in investigating the possibility that the leader peptide itself might be involved in such regulation(s). To examine this working hypothesis, one must determine the nature and the time course of the effect(s) exerted by the leader peptide on the processing and translocation of secretory proteins and in affecting the rate of secretion of already processed and sequestered secretory proteins.
Several steps of the processing-translocation phenomenon have been reconstituted in vitro, by using isolated microsomes (5, 6) . Synthetic leader peptide (SLP) of the preproparathyroid hormone has been shown to compete with the cell-free processing of various prehormones (14) . This implied that the interaction sites on the microsomal membranes are saturable and can recognize all leader peptides. However, the in vitro system could not provide conditions for following the time course of the leader peptide's interaction with these binding sites. In addition, the later steps in the secretion process of already sequestered proteins cannot be reconstituted under cell-free conditions.
Microinjected Xenopus oocytes offer an attractive surrogate system for such experiments. The oocytes are huge (1 mm in diameter) cells, secreting specific proteins via an exocytotic release of vesicle contents. This occurs both with oocyte endogenous proteins and with translation products of various microinjected mRNAs (15) . Protein secretion from the oocytes appears to be highly selective but neither cell type nor species specific (16) . Nascent polypeptide chains for secretory proteins become compartmentalized within vesicles during their synthesis in the oocytes (17) (18) (19) and are subsequently secreted in a processed form (19, 20) . When the mature proteins, rather than their mRNAs, are injected into the oocytes, they may become degraded in the oocyte and are not re-exported. This implies that secretion from the oocyte involves cotranslational events (16, 20) . Scarcity of putative membrane binding sites for such cotranslational events has been suggested as the limiting factor for translation of membrane-associated mRNAs in the oocytes (21) .
We now report that in microinjected Xenopus oocytes, SLP of mouse immunoglobulin light chain precursor segregates into the membrane fraction and modulates secretion of proteins in two ways. It inhibits secretion of nascent chains for secretory proteins. In addition, it selectively accelerates the rate of se- (24) , the adjacent two NH2-terminal residues of the mature light chain (Asp-Ile), one leucine, three glutamic acid residues, and one glycine as the COOH-terminal residue. The synthesis andisolation of the SLP will be published elsewhere. Iodination of the SLP was performed according to Bolton and Hunter (25) , and the iodinated peptide~was purified by gel filtration using Sephadex G-25 in 50 mM ammonium bicarbonate.
Antibodies against the purified SLP were elicited in rabbits and were purified by affinity chromatography on a Sepharose 4B column, to which the SLP was covalently bound (26) .
RNA was extracted from TEPC-15 mouse myeloma cells according to Kirby (27) . Poly(A)-containing mRNA was separated by oligo(dT)-cellulose chromatography (28) . Electrophoretic separation of proteins on polyacrylamide gradient gels in the presence of-NaDodSO4 was according to Laemmli (29) .
RESULTS
We examined the effect of SLP on protein synthesis by first injecting '50 ng of leader peptide into an. oocyte and subsequently incubating the oocyte in medium containing [3S]methionine and found a reproducible and marked inhibition of accumulation of labeled protein in the membrane of the oocyte (Fig. 1A) . Leader peptide also reduced the rate of methionine incorporation into proteins secreted from the oocytes to the medium (Fig. 1B) . The absolute-rate of protein synthesis in Xenopus oocytes has been reported to be about 20 ng/hr (31) .
Therefore, it appears that -the. amounts of SLP that inhibit the synthesis of secretory and membrane proteins are close to those that can be expected to exist in the oocytes under physiological conditions. The effect is rapid and time-dependent. It reaches a maximum of 50% inhibition in the membrane fraction at 30 min.after injection. The SLP-induced interference with secretion is delayed, compared to that in the membrane fraction, reaching a 40% maximum by 1 hr after.injection. The SLP-induced inhibition.of membrane-associated protein synthesis and secretion of the oocyte.proteins decays by 3 hr after injection, and after 6 hr the effect is no longer apparent. (Fig. 2B ). Similar observations were obtained when 500 ng of SLP was injected per oocyte (not shown). When 125I-labeled SLP was injected into the oocytes, almost half associated with the membrane fraction. It then disappeared from the membranes, possibly by degradation, in a -time-dependent manner that coincided with -the SLP-induced inhibition effect ( Fig. 2A) teins. Both the rate of secretion and the SLP-induced interference with secretion were much more apparent in the mRNAinjected than in the control oocytes (Table 1) . In both cases, the inhibition effect exerted by the injected SLP was specific to membrane-bound and secreted proteins. Thus, no decrease was observed in the rate of synthesis of soluble proteins in the control or the mRNA microinjected oocytes (Table 1) . Under these experimental conditions, the injected SLP appeared to interfere primarily with processes necessary for the secretion of myeloma proteins. This conclusion has been confirmed by NaDodSO4/polyacrylamide gel electrophoresis, which showed various distribution patterns for proteins secreted from control and mRNA-injected oocytes, in the presence and absence of coinjected SLP (Fig. 3) .
In the presence of mRNA, the block of secretion is most apparent when 250 ng of SLP is injected per oocyte. Twenty-five nanograms per oocyte does not affect secretion. The inhibition of secretion caused by 250 ng of SLP per oocyte increases from 62% at 1 hr after injection to 95% at 2 hr and decreases to 63% by 4 hr after injection. Thus, it appears that SLP competes both with endogenous and mRNA-directed incorporation of methionine into secreted and membrane proteins in microinjected oocytes. In contrast to this inhibition, which manifests itself by interfering with the post-translational processing or compartmentalization (or both) of newly formed polypeptide chains, SLP enhances the rate of secretion of already synthesized and sequestered proteins, which are destined for eventual secretion. This stimulation was apparent when increasing quantities of SLP were injected into oocytes that were preincubated with [3S]methionine for 18 hr. The rate of secretion of endogenous labeled, CCL3COOH-insoluble proteins from the SLP-injected oocytes was reproducibly accelerated in a dose-dependent manner. In oocytes injected with as little as 10 ng of SLP per oocyte, the rate of secretion was 2-fold higher than that of control oocytes at 2 hr after injection. The accelerated secretion increased up to 10-fold over control in oocytes injected with 50 ng of SLP per oocyte. Further increase of the SLP quantity injected, up to 500 ng per oocyte, did not affect the enhanced secretion (Fig. 4) . The absolute rate of protein synthesis in Xenopus oocytes has been reported to be about 20 ng/hr (31) . Therefore, it appears that the amounts of SLP that induce accelerated secretion are close to those that can be expected to exist in the oocytes under physiological conditions. Polyacrylamide gel electrophoresis of the secreted labeled proteins, followed by autoradiography of the dried gels, revealed a general increase in the intensity but no apparent differences between the size distribution patterns of the proteins secreted from SLPinjected or control oocytes (Fig. 4 Inset). Furthermore, we failed to see any morphological differences between control and SLPinjected oocytes, both by light or electron microscopy (not shown). Thus, it appears that microinjected SLP selectively speeds up the release into the incubation medium of polypeptides that are destined to be secreted but does not alter the morphological features of the oocytes nor does it affect the natural segregation pattern of proteins within the subcellular oocyte compartments.
[ (Fig. 5 A and B) . This indicates that the oocytes remain fully viable after the preincubation period, as it has been shown that active secretion of both oocyte proteins (15) and protein products of microinjected mRNAs (20, 22) continues to occur for many hours. Oocytes injected with 50 ng of SLP per oocyte display a rapidly induced secretion enhancement, and the concentration of secreted proteins in their incubation medium remains much higher than that of control oocytes for over 80 hr (Fig. 5A) . The initially high rate of protein secretion from these oocytes decreases exponentially, and by 20 hr after injection it already appears to be rather close to the secretion rate displayed by control oocytes (Fig. 5B) . The initial exponential decrease in the rate of secretion from SLPinjected oocytes indicates a rate of decay with a ti,2 of about 2 hr for the secretion enhancement effect.
Amino acid residues 2-15 in SLP are all hydrophobic, and the COOH terminus of the peptide is composed of negatively charged amino acids. To find out whether these properties are sufficient to induce accelerated secretion, we injected oocytes with 0.1% Triton X-100 or with 44 ,uM poly-L-glutamic acid. Neither of these controls affected the rate of secretion from the injected oocytes, which displayed levels of secreted proteins similar to those obtained from noninjected or from Barth medium-injected oocytes (Fig. 6) . Injection of increasing quantities of glucagon, a peptide of a similar molecular weight to that of SLP, ruled out the possibility that the small size of the peptide is a major element in inducing the accelerated secretion. Injection of Ala-Gly-Ser-Glu peptide has shown that this short peptide is not sufficient to induce the accelerated secretion by itself (not shown). Taken together, these control experiments confirm that the accelerated rate of secretion from SLP-injected oocytes may be due to the entire SLP molecule.
To further investigate the biological specificity of the enhancement effect, we reacted SLP with anti-SLP antibodies and then injected the mixture into the oocytes. Immunoreacted SLP failed to accelerate secretion. The loss of this biological function is not due to the presence of immunoglobulins in the injected material, because SLP preincubated and coinjected with normal rabbit immunoglobulins does not lose its capacity to induce accelerated secretion (Table 2 ). This result indicates that the domain(s) in SLP that interacts with the anti-SLP antibodies is essential for inducing the secretion enhancement effect. Leader peptide (1 mg/ml) was immunoreacted with purified rabbit anti-leader peptide antibodies or with normal rabbit immunoglobulins (25 The specificity of the secretion block exerted by SLP on simultaneously translated nascent secretory polypeptide chains is indicated from the observation that the synthesis of cytoplasmic proteins remained totally unaffected under conditions in which protein secretion and incorporation into the membrane were profoundly inhibited. This is in agreement with the differential capacity for translation and lack of competition between mRNAs that segregate to free and membrane-bound polysomes in the oocytes (21) .
The mechanisms by which SLP inhibits the translocation and secretion of simultaneously translated proteins and accelerates the secretion of sequestered proteins have not been determined. One or more of the steps required for translocation of nascent chains might be blocked by SLP. SLP might competitively inhibit (either or both) (a) the binding of nascent polypeptides to the cytoplasmic signal recognition protein (33) or (b) the interaction of the signal recognition protein complex with the docking protein in the membrane of the rough endoplasmic reticulum (10) . The rate at which "2I-labeled SLP segregates into the oocyte membrane coincides with the rate of inhibition of translocation and secretion. This indicates that the peptide operates at the cell membrane and favors the second possibility. When accelerating secretion of sequestered proteins, SLP might affect (c) the rate of later post-translational processing events, required for the formation of mature proteins. These probably occur on the membrane of the rough endoplasmic reticulum, as suggested by the in vitro glycosylation of vesicular stomatitis virus protein (34) . Alternatively, or in addition, SLP might enhance (d) the rate at which processed polypeptides reach the secretory vesicles or the movement of secretory vesicles towards the plasma membrane and their fusion with it (or both). Each of these steps might involve additional regulatory proteins, which may be pursued by further use of SLP-microinjected oocytes as a surrogate system.
The saturable translocation sites on microsomal membranes appear to recognize various leader peptides (14) . The mechanism by which protein secretion from the oocytes operates is neither cell type nor species specific (35 
